Ryzodeg®, a co-formulation of insulin degludec (70%) and insulin aspart (30%), contains the new-generation once-daily basal insulin degludec in a soluble formulation with insulin aspart.

First time in the history:

1. Ryzodeg® is the first and only soluble insulin combination of ultra-long-acting insulin degludec and rapid-acting insulin.


2. In Ryzodeg® the basal (IDeg) and prandial (IAsp) components do not interact and their distinct pharmacokinetic/pharmacodynamics profiles are not compromised by co-formulation.


3. Ryzodeg® demonstrates a significantly lower risk of overall and nocturnal hypoglycaemia while successfully achieving equivalent reductions in HbA1c.


4. Ryzodeg® can be administered once or twice daily with the main meal(s).